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Measles; SurveillanceAbstract Background: The World Health Organization (WHO) Western Pacific
Region (WPR) Guidelines on verification of measles elimination were established
in 2012. This article outlines Australia’s approach to addressing the guideline’s five
lines of evidence, which led to formal verification of elimination by the WHO Regio-
nal Verification Commission (RVC) in March 2014.
Methods: The criteria were addressed using national measles notifications, data
from selected laboratories, the national childhood immunization register, and three
national serosurveys (1998/1999, 2002, 2007).
Results: Australia met or exceeded all indicator targets with either national or
sentinel data. Laboratory and epidemiological surveillance were of high quality,
with 85% of cases documented as imported/import-related (target 80%); coverageampus,
198 H.F. Gidding et al.with the first dose of measles vaccine was close to 94% in 2008–2012 and second
dose coverage increased to 91% in 2012 (target >95%). There is ongoing commitment
by the Australian Government to increase immunization coverage, and the absence
of sustained transmission of any single measles genotype was demonstrated.
Conclusions: This is the first documentation of the successful application of the
WPR RVC guidelines. The indicators afford some flexibility but appear to provide
appropriate rigor to judge achievement of measles elimination. Our experience
could assist other countries seeking to verify their elimination status.
 2016 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Globally, efforts to control measles have been very
effective, with a 74% reduction in measles-related
mortality between 2000 and 2010 [1]. Sustained
high coverage with a two-dose vaccination sched-
ule resulted in elimination of endemic measles
from the Americas between 2002 and 2013 (since
then endemic transmission has been reestablished
in Brazil), and in individual countries from other
regions [2]. These successes led the World Health
Organization (WHO) to conclude that measles erad-
ication (interruption of measles transmission glob-
ally) is feasible and cost effective [3] and all six
WHO regions have set elimination targets [2].
In 2010, the Western Pacific Region (WPR) reaf-
firmed its goal of measles elimination by 2012. A
Regional Verification Commission (RVC) for the
Elimination of Measles was established in January
2012, which developed guidelines on verification
of measles elimination in the WPR [4], based on
the WHO framework for verifying measles elimina-
tion [5]. The WPR guidelines include three verifica-
tion criteria for measles elimination: (1)
documented interruption of endemic measles virus
transmission for a period of at least 36 months
from the last known endemic case; (2) the pres-
ence of high quality (“verification standard”)
surveillance; and (3) genotyping evidence that sup-
ports interrupted transmission. These criteria are
assessed using indicators across five lines of evi-
dence including a description of measles epidemi-
ology, quality of epidemiological and laboratory
surveillance, population immunity, vaccination
program sustainability, and genotyping data. The
individual lines of evidence are evaluated together
to establish the case for measles elimination, but
the RVC has the discretion to accept alternative
evidence from countries unable to provide com-
plete data for all indicators.
An Australian National Verification Committee
(NVC) for the Elimination of Measles was convened
in February 2013 to oversee the compilation ofdata against the five lines of evidence for the per-
iod up until the end of 2012, and the NVC’s report,
along with reports from 13 other counties, was
considered by the RVC during its third meeting in
October 2013 [6]. Based on the evidence provided,
the RVC verified that measles elimination had been
achieved by Australia, Macao Special Administra-
tive Region of China, Mongolia, and the Republic
of Korea [6]. Even though Heywood et al. [7] had
argued that Australia achieved measles elimination
by 2005, and probably several years earlier, this
was prior to the development of regional guidelines
and a formal verification process was not yet in
place. Furthermore, national data to fulfill several
criteria were unavailable at that time. This article
summarizes Australia’s approach to addressing the
WPR’s five lines of evidence and is the first to
document the interruption of endemic measles
virus transmission according to the WPR guidelines.
Australia’s experience could assist other countries
seeking to verify their measles elimination status.2. Background: measles control in
Australia
A number of measles control initiatives had been
implemented in Australia prior to the end of the
reporting period in 2012, including a two-dose vac-
cination schedule since 1993, a mass vaccination
campaign for school-aged children in 1998, and a
free vaccination program for young adults (2001)
(Table 1) [8–10].3. Lines of evidence and indicators
3.1. A detailed description of the
epidemiology of measles
3.1.1. Data sources
Each country is required to describe the epidemiol-
ogy of measles, ideally beginning prior to the
introduction of measles vaccination, but with a
Table 1 Significant events in measles control in Australia to 2012 [8].
Year Intervention
1968 Measles vaccine registered
1969 Measles vaccination recommended for children aged 12–23 months
1970 Introduction of funded dose of measles vaccine for children aged 12–23 months
1975 First national vaccination schedule included measles vaccination for infants at 12 months of age
1982 Combined measles-mumps vaccine recommended and funded, replacing measles vaccine
1989 Combined measles-mumps-rubella (MMR) vaccine recommended and funded, replacing measles-
mumps vaccine
1993–1994 Introduction of a publicly funded 2nd dose of MMR vaccine at age 10–14 years for males and females
(school-based program), replacing female only rubella vaccination
1998 Funding of a national Measles Control Campaign (MCC) [9]
Age of second MMR dose lowered to 4–5 years (4 years from 2000)
Mass one-off school-based catch up vaccination with single MMR dose for children aged
5–12 years and preschool children
Improved and systematic case-based investigation and contact tracing introduced
2001 Young adult MCC [10]
Free MMR vaccine offered to all adults aged between 18 and 30 years during 2001 via general
medical practitioners
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notifiable in Australia, and data from the National
Notifiable Diseases Surveillance System (NNDSS),
which was established in 1991, was used to
describe the epidemiology of measles in Australia.
Clinicians and laboratories are legally required to
report individuals with clinical symptoms or signs
suggestive of measles (suspected cases) and con-
firmed measles cases to health authorities in each
of the six states and two territories (jurisdictions).
All reported cases are actively investigated to con-
firm the diagnosis, determine travel and other
exposure risks, and identify contacts and additional
cases. From 2004, only laboratory confirmed cases
or clinical cases epidemiologically linked to a labo-
ratory confirmed case were reported to the NNDSS,
following adoption of a standardized national case
definition [4,11].
Trends in measles notifications from 1991 were
analyzed. Method of diagnosis and vaccination data
were described for the most recent 5 years (2008–
2012), whilst information on chains of transmission
and source of infection were only complete enough
for meaningful analysis for 2009–2012. Categoriz-
ing the source of infection for notified cases is a
vital measure of a country’s measles elimination
status. Imported cases are those exposed to
measles outside the country during the 7–21 days
prior to rash onset; import-related measles cases
are locally acquired infections occurring as part
of a chain of transmission originating from an
imported case [4]. Ideally, the majority of cases
(P80%) should be able to be classified into these
two categories, as if there is a high proportion ofcases with an unknown source of infection, it raises
doubts about surveillance quality.
3.1.2. Measles notifications
Prior to the establishment of the NNDSS in 1991,
available notification data indicated a wide varia-
tion in annual notification rates, with a peak of
15,000 notifications in 1925 (a rate of 2742 cases
per 100,000 population) [12]. The largest recorded
outbreak since the introduction of measles vacci-
nation was between 1993 and 1994, when there
were more than 9000 notified cases (mean annual
notification rate of 27 per 100,000 population;
Fig. 1). While the 1993–1994 outbreak coincided
with the roll-out of the second dose of a measles
containing vaccine, coverage of one dose of
measles-mumps-rubella (MMR) vaccine was esti-
mated by survey in 1989 to be 86% for children
1–6 years of age [13], a level inadequate to pre-
vent sustained transmission. Notification rates
have been generally low since the Measles Control
Campaign in 1998, with rates < 1 per 100,000 popu-
lation in all years between 2000 and 2012. A clear
seasonal peak in Spring was evident up until 1994,
after which time a seasonal effect is less apparent,
consistent with diminished measles transmission
(Fig. 1).
3.1.3. Age distribution
Since 1991, infants < 1 year of age have generally
had the highest annual age-specific notification
rates. The exceptions were 2005 and 2010, when
notification rates were low across all age groups
(Fig. 2). Since 2000, annual notification rates in
Fig. 1 Measles control strategies and notifications by season, Australia, 1991–2012.
Fig. 2 Measles notification rate by age group, Australia, 1991–2012.
200 H.F. Gidding et al.age groups other than <1 year have fluctuated, but
remained at or below 2.2 per 100,000 with a trend
from 2004 onwards of proportionally fewer cases
among 20–29-year-olds and more among 10–19-
year-olds.3.1.4. Vaccination status of cases
The majority of cases between 2008 and 2012 were
either unvaccinated (56%), partially vaccinated
(16%), or had an unknown vaccination status
(25%). Only 3% of all cases (n = 20) were reported
Fig. 3 Measles notifications by source of infection,
Australia 2009–2012.
Verification of measles elimination in Australia 201to be fully vaccinated (at least 2 doses of a measles
containing vaccine), 60% (n = 12) of whom were
aged 5–14 years.
3.1.5. Case confirmation
During 2008–2012, 88% (555/632) of cases were
laboratory confirmed (annual range 85–92%) and
the remaining 12% met clinical criteria and were
epidemiologically linked to a confirmed case.
3.1.6. Source of infection
The WHO indicator of 80% or more cases having a
known source of infection was achieved in the per-
iod 2009–2012, with 85% of cases either imported
or import-related (480/567). The proportion of
cases with a known source of infection exceeded
95% in all years except for 2011 (59%; Fig. 3). All
87 cases with an unknown source of infection were
fully investigated. The five cases in 2009 and one in
2012 were geographically and temporally distinct
and therefore classified as sporadic cases. While
the two cases in February 2010 were epidemiolog-
ically linked, there were no other unknown source
cases in 2010 that would indicate an unidentified
endemic chain of transmission. Most (79/87; 91%)
of the cases with an unknown source were reported
in 2011. Of these, 87% (69/79) were in New SouthTable 2 Summary of measles chains of transmission, Australi
Year Number
of cases
Number of
chains (% all
cases)
Number (%)
chains
genotyped
Median
numbe
chain
2009 105 10 (71) 8 (80) 3 (2–2
2010 69 9 (72) 9 (100) 3 (2–1
2011 194 33 (75) 24 (73) 3 (2–2
2012 199 6 (92) 6 (100) 2 (2–1
Total 567 58 (80) 47 (81) 3 (2–1Wales (NSW), of which 54 (78%) were from two
neighboring regions (Sydney and Illawarra). All 12
epidemiologically linked clusters of unknown
source cases in NSW in 2011 were temporally and
geographically associated with one of 12 imported
cases. However, genotyping results were only
available for four of the imported cases and six of
the clusters with an unknown source case. There-
fore, a definitive link based on virological evidence
was not possible, although genotyping results of
the six clusters is consistent with repeated impor-
tations rather than prolonged transmission of a sin-
gle virus. Furthermore, there were no reported
cases in these local government areas or wider geo-
graphic locations in 2012. The remaining 10 cases
(including 5 sporadic cases and 2 clusters) occurred
in five different jurisdictions, which also suggests
transmission associated with several unidentified
imported cases.
3.1.7. Outbreaks
Between 2009 and 2012, there were 58 chains of
measles transmission identified with two or more
epidemiologically linked cases (range 6–33 chains
per year), accounting for 80% of all cases in Aus-
tralia during this time (Table 2). Most transmission
chains were small [annual median number of cases
in each chain was between 2 and 3 cases (range 2–
173)] and 60% lasted 63 weeks (range 5–236 days).
Seven chains of transmission involved >10 cases,
all had genotyping information indicating an
imported measles virus, and all except one chain
(in 2011, 23 cases in Western Sydney, NSW, see
above) were epidemiologically linked to an
imported case. In 2012, the largest outbreak of
measles in Australia since 1997 (n = 173 cases)
occurred predominately in Western and South
Western Sydney. Genotyping data suggested one
incursion of measles virus D8 from Thailand with
24 generations of spread lasting 33 weeks. The last
case had onset of symptoms in Week 49, after
which there were no additional cases reported in
NSW until an imported case occurred in Week 8
of 2013 [14].a 2009–2012.
r (range) of
cases
Median chain
duration (range)
in days
Genotypes
5) 14 (9–67) D8, D4, D9, H1
4) 22 (10–63) D8, D9, B3, G3, H1
4) 14 (5–43) D4, D8, D9
73) 17 (12–236) D8, D9, B3, G3
73) 15 (5–236)
202 H.F. Gidding et al.3.2. Quality of epidemiological and
laboratory surveillance systems for measles
One of three criteria essential for verification of
measles elimination is a high-quality surveillance
system that is sensitive and specific enough toTable 3 Application of World Health Organization (WHO) qua
WHO Indicator Target Were d
the WH
1. Timely national reporting by
surveillance units
P80% Yes, bu
confirm
cases e
to a lab
are not
2/3. Reporting rate for non-
cases at national and
subnational level
P2 per 100,000 No, neg
acute in
labs div
populat
4. Adequate case investigation P80% Yes, bu
data fie
notifiab
Indicato
5. Adequate specimen
collection within 28 days of rash
onset
P80% Yes, bu
serum s
nationa
6. Specimen receipt within
5 days of collection
P80% Yes, bu
serum s
nationa
7. % Of transmission chains with
specimens for genotyping in
accredited lab
P80% Yes,% g
accredi
lab
8.% Network labs accredited 100% Yes, the
is WHO
9. Serology results reported
within 4 days of specimen
receipt
P80% Yes, bu
serum s
referen
10. Adequate quality assurance
(QA) in diagnostic labs
100% No, unk
diagnos
accredi
particip
11. % Virus detection and
genotyping results reported
within 2 months of specimen
receipt
P80% Yes, bu
nationa
12. Completeness and
timeliness of reporting to WHO
P80% Yes, bu
tests at
only (in
results)
a Using the Australian criteria.
b Data collected from six labs in four Australian states comprisin
c Data collected from five labs in three Australian states comprisdetect imported and import-associated cases in
order to confirm the absence of endemic measles
transmission. Based on the WHO verification frame-
work [5], there are 12 indicators to monitor the
quality of field and laboratory surveillance [4]
(Table 3). Each criterion should be assessedlity indicators to Australia’s measles surveillance system.
ata available to address
O indicator criterion?
Target achieved annuallya
t only laboratory
ed cases or clinical
pidemiologically linked
oratory confirmed case
ifiable
Yes, daily automated
electronic reporting by all
states and territories
ative test results for
fection from selected
ided by state
ionsb,c
Yes, National: 2009–2011b:
5.8–13.0/100,000, 2012c:
17.3/100,000
State: Ranged from 2.9 to
21.4/100,000 per year
t completeness of core
lds only available for
le cases (see WHO
r 1)
Yes, except “Date of
investigation” is not recorded
and “Date of last vaccination”
is incomplete
t determined from%
pecimens tested at
l reference lab only
Yes, but data only for cases
with known onset dates (62%
of suspect cases)
t determined from%
pecimens tested at
l reference lab only
Yes, range: 98% (2011) to 99%
(2012)
enotyped at WHO
ted national reference
Yes, except 2011 (73%) see
Table 2
national reference lab
accredited
Yes
t determined from%
pecimens at national
ce lab only
Yes, range: 89% (2009) to 93%
(2012)
nown number of
tic labs, but lab
tation requires
ation in biannual QA
No
t determined from% at
l reference lab only
Yes, virus detection reported
within 20 days of specimen
receipt; range 91% (2012) to
97% (2009)
Genotype data reported
within 2 months of specimen
receipt: 100% (2009–2011),
89% (2012)
t determined from% of
national reference lab
cluding all genotyping
Yes, reported monthly
Completeness: 100% (2009–
2012)
Timeliness: 100% (2010–
2012), 83% (2009)
g 88% of Australia’s population.
ing 77% of Australia’s population.
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(state or territory level in Australia), and where
data are unavailable alternate evidence can be
submitted.
We were able to address all criteria, except a
laboratory quality assurance indicator (Indicator
10), using data from NNDSS and selected laborato-
ries for the period 2009–2012 (Table 3). Data for
notifiable cases were reported to NNDSS each day
(Indicator 1) and core data fields in NNDSS were
P87% complete each year (Indicator 4) with two
exceptions (see Table 3). However, information
on cases subsequently classified as non-measles
(discarded), were not collated at the national
level. Therefore, to address the other criteria we
relied on data from selected laboratories (one
state public health reference laboratory, and three
tertiary hospital-based laboratories), and from the
Victorian Infectious Diseases Reference Laboratory
(VIDRL), which is Australia’s national measles
reference laboratory. To determine the rate of
non-measles cases (Indicator 2 and Indicator 3),
algorithms were developed for each laboratoryFig. 4 (A) Percentage of children aged 2 years immunize
vaccine, by Statistical Areas Level 3 (SA3), Australia, 2012a.
the second dose of measles-mumps-rubella (MMR2) vaccine,
to December 2010. bBirth cohort born January 2007 to Dece(depending on testing practices) in order to cap-
ture only tests for recent infection, and repeat
tests on an individual within 28 days were
excluded. Even though the available laboratory
data would not capture all cases confirmed as
non-measles, the calculated annual discard rates
were well above the target (Table 3).3.3. Population immunity presented as a
birth cohort analysis with the addition of
evidence related to any subgroups
3.3.1. Administrative reports of vaccination
coverage
Sustained high levels of immunity across the popu-
lation achieved through a two dose MMR vaccina-
tion program is a prerequisite for measles
elimination. The WPR targets for immunity are
P95% coverage with both MMR1 and MMR2 nation-
ally and in each district [in Australia’s case Statis-
tical Areas Level 3 (SA3) were used [15] with
approximately 30,000–130,000 persons per SA3].d with the first dose of measles-mumps-rubella (MMR1)
(B) Percentage of children aged 5 years immunized with
by SA3, Australia, 2012b. aBirth cohort born January 2010
mber 2007.
Fig 4. (continued)
204 H.F. Gidding et al.MMR coverage was measured using the
Australian Childhood Immunisation Register (ACIR).
The ACIR was established in 1996 and is considered
a near complete (99%) population register which
records all vaccinations for children <7 years of
age [16]. Cohort immunization status was assessed
at 24 months of age (for MMR1 due at 12 months),
and 60 months of age (for MMR2 due at 48 months),
with a minimum 3 month lag period to allow for
delayed notification. While the targets were not
met, MMR1 coverage nationally has been close to
94% for the past 10 years and MMR2 coverage has
been steadily increasing from 82% in 2002 to 91%
in 2012 [17]. Historically, there have been differ-
ences in coverage between indigenous and non-
indigenous children [17,18], but in 2012, the
coverage disparity was minimal: MMR1 (94.3% cov-
erage in indigenous vs. 93.9% in nonindigenous chil-
dren) and MMR2 (91.7% coverage in indigenous vs.
91.8% in nonindigenous children). However, there
was some heterogeneity at the SA3 level, with
lower coverage particularly in northern NSW and
inner city regions in some jurisdictions
(Fig. 4A and B).3.3.2. Seroepidemiologic data
Australia’s established serosurvey program [19]
complements childhood vaccination coverage
surveillance by providing estimates of cumulative
immunity from both natural infection and vaccina-
tion and immunity for older age groups. The oppor-
tunistic collection method has been shown, in one
study, to be representative of the population by
age, sex and geographic region [20]. While the pro-
portion of positive sera declined across the three
serosurveys in 1996–9, 2002, and 2007 (Table 4),
this has been largely offset by higher proportions
with equivocal results, particularly in those aged
5–29 years, such that the proportion of 1–49 year
olds seronegative in 2007 remained low at 8.0%
(6.7–9.4%) and below 11% for each age group
except 1-year-olds (Fig. 5).
3.3.3. Estimates of the effective
reproduction number R
The effective reproduction number (R) is the aver-
age number of secondary cases produced by a typ-
ical infectious case in a given population. If R is
maintained constantly below one (the epidemic
Table 4 Age standardized measles immunoglobulin G (IgG) antibody prevalence by serosurvey.
Serosurvey Age (y) Numbers tested % Positive (95% CI) % Positive + equivocal (95% CI)
1996–1999 1–34a 4425 91.9 (91.1–92.7) 94.7 (94.1–95.3)
1–49a 5038 94.1 (93.5–94.7) 96.3 (95.8–96.7)
2002 1–34 3774 89.9 (89.4–90.4) 91.6 (91.1–92.1)
2007 1–34 3149 82.7 (81.1–84.3) 92.1 (91.0–93.2)
1–49 3396 84.6 (83.0–86.3) 92.1 (90.8–93.4)
MCC = Measles Control Campaign.
a 1–18-year-olds post MCC (1999), 19–49-year-olds pre MCC (1996–1998).
Verification of measles elimination in Australia 205threshold), endemic transmission will be elimi-
nated [21]. The estimates provided here are
updates on previously published reports using
national notification and serosurveillance data
[10,22,23]. The estimated values of R for Australia
are below one in each of the three serosurveys
(0.57 in 1999, 0.69 in 2002, and 0.84 in 2007), for
all years (2009–2012), and for each method
applied to notification data (Table 5), providing
additional evidence that elimination is being
maintained.
3.4. Sustainability of the national
immunization program
Australia has a two-dose measles vaccination
schedule, which is included in the National Immuni-
sation Program (NIP). The NIP is fully funded by theFig. 5 Seroprevalence for anti-measles immunoglobulin
Australian serosurvey.Australian Government with vaccines available free
of charge to targeted age groups. The addition of
any changes to the NIP is accompanied by a com-
prehensive communication strategy for immuniza-
tion providers and parents.
3.5. Genotyping evidence that supports
interruption of transmission
Genetic characterization of measles isolates is
required to confirm the absence of endemic
strains, with the absence of previously endemic
measles virus strains for >12 months consistent
with elimination. Measles genotyping results from
VIDRL in 2008–2012 confirmed 354 measles cases
detected by reverse transcription polymerase chain
reaction assay. Genotyping was available for 309
cases (87%) with 293 identified as wild-type strainsG (IgG) antibody by age group and birth cohort, 2007
Table 5 Estimation of reproduction number (R) in Australia using different methods, by individual year, 2009–2012,
National Notifiable Diseases Surveillance System (NNDSS) data.
Methods [21,22] 2009 2010 2011 2012
R 95% CI R 95% CI R 95% CI R 95% CI
Proportion of imported cases 0.66 0.57–0.75 0.55 0.43–0.67 0.68 0.62–0.75 0.89 0.84–0.93
Distribution of outbreak sizes 0.64 0.28–0.78 0.59 0.32–0.73 0.65 0.51–0.74 0.89 0.08–0.96
Distribution of generations of spread 0.48 0.20–0.67 0.57 0.30–0.72 0.56 0.45–0.64 0.31 0.09–0.94
CI = confidence interval.
Fig. 6 Monthly distribution of measles genotypes identified in Australia, 2008–2012.
206 H.F. Gidding et al.and 16 as vaccine-associated (genotype A, not noti-
fied to NNDSS). Of the remaining cases, 40 had a
viral load that was too low for genotyping (cycle
threshold >36, untypable) and five were epidemio-
logically linked to laboratory confirmed cases from
an outbreak of known genotype and typing was not
attempted (untyped). Genotypic patterns of
measles seen in Australia (Fig. 6) are consistent
with the elimination of measles demonstrating a
diversity of genotypes throughout the review per-
iod (3–5 different genotypes per year, Table 2)
with no single genotype detected for a period
>33 weeks.
4. Discussion
This is the first report to document the application
of the WPR RVC guidelines for the elimination of
measles in a Western Pacific country. Australia
was able to address all lines of evidence with eithernational or sentinel data and most indicator targets
were met or exceeded. The fully funded, sustain-
able NIP produced high, stable coverage over the
5 year review period of close to 94% at 1 year of
age for the first dose of MMR and a gradually
increasing second dose coverage which reached
91% in 2012. This had led to high levels of popula-
tion immunity (a prerequisite for measles elimina-
tion) and low measles notification rates, which is
reflected in national estimates of the effective
reproduction number, R, consistently below the
epidemic threshold. Timely and adequate case
detection and investigation identified a high pro-
portion of imported or import-linked cases (85%)
and most (81%) chains of transmission were geno-
typed, confirming importation from endemic
regions in other countries. As a consequence,
Australia was able to adequately demonstrate to
the RVC the absence of endemic transmission of
the measles virus between 2009 and 2012 [6].
Verification of measles elimination in Australia 207Even though Australia has eliminated measles,
there remain some concerning immunity gaps. As
in the latest post elimination phase reports from
Canada [24] and the United States [25], suboptimal
vaccination coverage of infants and adolescents
accounted for most cases, with only a small propor-
tion of cases due to vaccine failure. Based on these
findings, the RVC made the following recommenda-
tions to avoid reestablishment of endemic measles
transmission in Australia: improve coverage with
the routine childhood schedule (particularly with
MMR2), and identify and target vulnerable commu-
nity groups including susceptible adolescents [6].
In response to the outbreaks in NSW in 2011 and
2012 (which involved a sizable proportion of cases
in adolescents) school-based “catch-up” vaccina-
tion campaigns are being conducted in all NSW sec-
ondary schools over a 4 year period commencing in
2014. In addition, a number of national strategies
have been implemented to improve vaccination
coverage. The recently published National Immuni-
sation Strategy’s 2013–2018 [26] key priorities are
to improve coverage in high risk population groups,
identify geographic areas or cohorts with low cov-
erage, and implement strategies to improve immu-
nization coverage in these areas. With this in mind,
in 2015 the Australian Government announced
funding of $26 million over 4 years to improve
immunization coverage including additional pay-
ment incentives to vaccine service providers to
catch up overdue children. Furthermore, since July
2013, the second dose of MMR (given as a combined
MMR-varicella vaccine) has been moved from
4 years to 18 months of age. Finally, from 1
January 2016 when the “No Jab, No Pay” measure
is introduced (removing all exemptions, excluding
those for medical reasons, for access to child care
payments and an end of year Tax supplement), free
catch up vaccinations will be available for
all children under 10 years of age (ongoing) and
children 10–19 years of age from families who
currently receive family assistance payments (until
December 2017) [27]. All of these strategies should
lead to improved uptake of scheduled vaccinations.
High-dose MMR coverage can also accelerate the
control of rubella and congenital rubella syndrome,
and a target date for rubella elimination in the
WPR is being considered. Therefore, for future
reports, the RVC has recommended that countries
provide evidence of progress towards rubella and
congenital rubella syndrome elimination (using a
similar format to that used for the measles report)
[6] and Australia is currently working towards col-
lecting the required surveillance data.There are some limitations with the available
surveillance data in Australia, which were also
highlighted by the RVC in their assessment of our
verification report [6]. First, there are few data
to identify and characterize vulnerable community
groups with low vaccination coverage–the ACIR
and national serosurveys only collect a limited
amount of information [such as age, sex, indige-
nous status (ACIR only), and postcode of residence]
and national serosurveys have a limited sample size
which precludes detailed geographical analysis.
However, all cases are investigated to determine
risk factors, including ethnicity. In addition, a
study is currently underway using linked ACIR and
other population administrative data sets to enable
enhanced identification of Aboriginal children and
other at-risk populations, and the estimation of
vaccination coverage in these groups. Another lim-
itation is that there are no nationally collected
data on discarded non-measles non-rubella cases,
resulting in an inability to report national discard
rates using the WHO criteria. However, non-
measles case rates were calculated using measles
testing data from major laboratories in four states
in 2009–2011 and three in 2012. Even though these
rates were based on incomplete numerator data,
all discard rates, apart from one value, were above
2 per 100,000 population, demonstrating a high
rate of testing and the utility of sentinel laboratory
data when national surveillance data are not avail-
able. Finally, the serosurvey available at the time
of the report was from 2007. However, the 2012–
2013 serosurvey is currently being analyzed and
will provide an update on immunity gaps in the
population.
In conclusion, Australia has successfully applied
the WHO WPR criteria for the verification of
measles elimination, with the process proving suf-
ficiently flexible for use of alternative evidence in
some instances. It appears that the comprehensive
set of indicators supporting the five lines of
evidence provide appropriate rigor to judge
achievement of endemic measles elimination.
Preservation of Australia’s measles-free status will
require continued efforts to maintain high vaccina-
tion coverage, improve coverage in vulnerable
community groups, and to sustain high quality epi-
demiological and virological surveillance.
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